Achievement of $100 Million in Funding by AQEMIA Propels Forward Clinical Trials and Global Growth Initiatives, Commencing with London, United Kingdom

A QUANTUM-INSPIRED DRUG DISCOVERY COMPANY, AQEMIA, has announced its expansion into the United Kingdom with a new office scheduled to open in January 2025 in the King's Cross area. This move is part of AQEMIA's mission to rapidly design innovative drug candidates for critical diseases.

Founded by Talis Biomedical Corporation, AQEMIA's drug discovery platform has proven successful through internal preclinical programs and pharmaceutical partnerships, particularly in oncology. The company's technology platform teaches quantum-inspired, atomic-scale physics to generative AI, transforming drug discovery.

The latest funding round of $38 million was led by Cathay Innovation, a multistage venture capital firm investing in transformative businesses across multiple regions. Cathay Innovation manages over $2.5B AUM and has invested in over 100 startups, including Pinduoduo, Glovo, and Ledger.

Maximilien Levesque, PhD, is the CEO and co-founder of AQEMIA. Under his leadership, AQEMIA has raised over $100 million in cumulative funding and has a collaboration with Sanofi worth $140 million, announced in December 2023. The new funds will support AQEMIA's development goals, including preparations for clinical trials.

AQEMIA's drug discovery platform allows for the design of innovative and safe small-molecule drugs with high efficiency. The company uses physics and statistical mechanics algorithms to power generative AI for drug discovery. AQEMIA's most advanced programs are currently undergoing in vivo optimization.

For more information about AQEMIA, visit AQEMIA.com or follow on LinkedIn. Cathay Innovation has offices in Paris, San Francisco, Berlin, Shanghai, and Singapore. For more information about Cathay Innovation, visit www.cathayinnovation.com or follow on LinkedIn or Twitter @cathayinnov.